Juergen Wasem

Dr. Juergen Wasem

orcid

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2023 in Journal of Medical Internet Research
Verified
Journal Article
Open access
GGGodwin Denk Giebel
Godwin Denk Giebel
CSChristian Speckemeier
Christian Speckemeier
CACarina Abels
Carina Abels
FPFelix Plescher
Felix Plescher
KBKirstin Börchers
Kirstin Börchers
SNSilke Neusser
Silke Neusser
Background: The digitization of health care led to a steady increase in the adoption and use of mobile health (mHealth) apps. Germany is the first country in the world to cover the costs of mHealth apps through statutory health insurance. Although the benefits of mHealth apps are discussed in detail, aspects of problems and barriers are rarely studied. Objective: This scoping review aimed to map and categorize the evidence on problems and barriers related to the use of mHealth apps. Methods: Systematic searches were conducted in the MEDLINE, Embase, and PsycINFO databases. Additional searches were conducted on JMIR Publications and on websites of relevant international organizations. The inclusion criteria were publications dealing with apps similar to those approved in the German health care system, publications addressing problems and barriers related to the use of mHealth apps, and articles published between January 1, 2015, and June 8, 2021. Study selection was performed by 2 reviewers. The manuscript was drafted according to the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) checklist. The analysis of the included publications and categorization of problems and hurdles were performed using MAXQDA (VERBI Software GmbH). Results: The database search identified 1479 publications. Of the 1479 publications, 21 (1.42%) met the inclusion criteria. A further 8 publications were included from citation searching and searching in JMIR Publications. The identified publications were analyzed for problems and barriers. Problems and barriers were classified into 10 categories (“validity,” “usability,” “technology,” “use and adherence,” “data privacy and security,” “patient-physician relationship,” “knowledge and skills,” “individuality,” “implementation,” and “costs”). The most frequently mentioned categories were use and adherence (eg, incorporating the app into daily life or dropouts from use; n=22) and usability (eg, ease of use and design; n=19). Conclusions: The search identified various problems and barriers in the context of mHealth apps. Although problems at the app level (such as usability) are studied frequently, problems at the system level are addressed rather vaguely. To ensure optimal use of and care with mHealth apps, it is essential to consider all types of problems and barriers. Therefore, researchers and policy makers should have a special focus on this issue to identify the needs for quality assurance. International Registered Report Identifier (IRRID): RR2-10.2196/32702

18 October 2005 in Das Gesundheitswesen
Verified
Journal Article
Closed access
PDF file
CKC Krauth
C Krauth
FHF Hessel
F Hessel
THT Hansmeier
T Hansmeier
JWJuergen Wasem
Juergen Wasem
RSR Seitz
R Seitz
BSB Schweikert
B Schweikert
Ein zentraler Bestandteil vieler gesundheitsökonomischer Untersuchungen ist die Messung krankheitsbedingter Kosten. Für die Methodik der Kostenmessung wurden verschiedene, unterschiedlich detaillierte Leitlinien formuliert, die aber insbesondere hinsichtlich der konkreten Bewertung der konsumierten Ressourcen unbestimmt blieben. In dem vorliegenden Beitrag wird ein Vorschlag für die Vereinheitlichung der monetären Bewertung von Gesundheitsleistungen im Follow-up-Zeitraum (nach der zu evaluierenden Intervention) präsentiert. Dabei liegt die gesellschaftliche Perspektive zugrunde. Es werden die wichtigsten direkten und indirekten Kostenkomponenten berücksichtigt: ambulant-ärztliche Versorgung, Medikamente, Heil- und Hilfsmittel, stationäre Aufenthalte, Arbeitsunfähigkeitstage und Erwerbsunfähigkeit. Die Bewertungssätze basieren auf administrativen Kostensätzen oder werden von amtlichen Statistiken abgeleitet. Die Ermittlung der aktuellst verfügbaren Bewertungssätze beruht überwiegend auf empirischen Daten aus den Jahren 2002 und 2003. Mit dem vorgeschlagenen Preisgerüst wird auf eine durchschnittliche Bewertung von Gesundheitsleistungen abgestellt. Damit werden die Ergebnisse unterschiedlicher gesundheitsökonomischer Studien vergleichbar. Die meisten Kostenkomponenten basieren nicht auf Marktpreisen, sondern auf administrativ bedingten Vergütungssätzen. Dies impliziert, dass institutionelle Änderungen, wie sie im Gesundheitswesen nicht selten sind, auch die Bewertungssätze beeinflussen (bspw. Einführung von DRGs) und daher bei der zukünftigen Aktualisierung berücksichtigt werden müssen. Measurement of health care costs is a crucial task in health economic evaluation. Various guidelines with different amount of details have been set up for costing methods in economic evaluation which, however, do not precisely stipulate how to value resource consumption. In this article we present a proposal for the standardisation of the monetary valuation of health care utilisation occurring in the follow up period after the actual intervention to be evaluated. From a societal perspective the primary direct and indirect cost components are considered, such as outpatient medical care, pharmaceuticals, non-physician health services, inpatient care, days of sick leave and early retirement due to sickness. The standard costs are based on administrative charges and rates or on official statistics. They are based on the most current data sources which are mainly from 2002 and 2003. This system of standard costs aims at an average valuation of resource consumption. This makes for the comparability of different health economic studies. Most standard costs are not based on market prices but on administratively specified charges and rates. This implies that institutional changes which are quite common in the health care system, may also affect the valuation rates, for example the introduction of DRGs. This should be taken into account when updating the system of standard costs.

1 March 2003 in Gut
Verified
Journal Article
Closed access
PDF file
Uwe SiebertUwe Siebert
Uwe Siebert
GSG Sroczynski
G Sroczynski
SRS Rossol
S Rossol
JWJuergen Wasem
Juergen Wasem
URU Ravens-Sieberer
U Ravens-Sieberer
JWJ B Wong
J B Wong
Background: Peginterferon α-2b plus ribavirin therapy in previously untreated patients with chronic hepatitis C yields the highest sustained virological response rates of any treatment strategy but is expensive. Aims: To estimate the cost effectiveness of treatment with peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of patients with chronic hepatitis C. Methods: Individual patient level data from a randomised clinical trial with peginterferon plus ribavirin were applied to a previously published and validated Markov model to project lifelong clinical outcomes. Quality of life and economic estimates were based on German patient data. We used a societal perspective and applied a 3% annual discount rate. Results: Compared with no antiviral therapy, peginterferon plus fixed or weight based dosing of ribavirin increased life expectancy by 4.2 and 4.7 years, respectively. Compared with standard interferon α-2b plus ribavirin, peginterferon plus fixed or weight based dosing of ribavirin increased life expectancy by 0.5 and by 1.0 years with incremental cost effectiveness ratios of 11 800 and 6600 per quality adjusted life year (QALY), respectively. Subgroup analyses by genotype, viral load, sex, and histology showed that peginterferon plus weight based ribavirin remained cost effective compared with other well accepted medical treatments. Conclusions: Peginterferon α-2b plus ribavirin should reduce the incidence of liver complications, prolong life, improve quality of life, and be cost effective for the initial treatment of chronic hepatitis C.

1 July 2008 in Value in Health
Verified
Journal Article
Closed access
JSJ.-Matthias Graf von der Schulenburg
J.-Matthias Graf von der Schulenburg
WGWolfgang Greiner
Wolfgang Greiner
FJFred Jost
Fred Jost
NKNorbert Klusen
Norbert Klusen
MKMaria Kubin
Maria Kubin
CWChristian Weber
Christian Weber

1 March 2013 in Health Policy
Verified
Journal Article
Closed access
WVWynand P.M.M. van de Ven
Wynand P.M.M. van de Ven
KBKonstantin Beck
Konstantin Beck
FBFlorian Buchner
Florian Buchner
ESErik Schokkaert
Erik Schokkaert
FSF.T. (Erik) Schut
F.T. (Erik) Schut
JWJuergen Wasem
Juergen Wasem

17 October 2015 in PharmacoEconomics
Verified
Journal Article
Open access
PDF file
BUBernhard Ultsch
Bernhard Ultsch
ODOliver Damm
Oliver Damm
PBPhilippe Beutels
Philippe Beutels
JBJoke Bilcke
Joke Bilcke
BBBernd Brüggenjürgen
Bernd Brüggenjürgen
OWOle Wichmann
Ole Wichmann
Background Incremental cost-effectiveness and cost-utility analyses [health economic evaluations (HEEs)] of vaccines are routinely considered in decision making on immunization in various industrialized countries. While guidelines advocating more standardization of such HEEs (mainly for curative drugs) exist, several immunization-specific aspects (e.g. indirect effects or discounting approach) are still a subject of debate within the scientific community. Objective The objective of this study was to develop a consensus framework for HEEs of vaccines to support the development of national guidelines in Europe. Methods A systematic literature review was conducted to identify prevailing issues related to HEEs of vaccines. Furthermore, European experts in the field of health economics and immunization decision making were nominated and asked to select relevant aspects for discussion. Based on this, a workshop was held with these experts. Aspects on ‘mathematical modelling’, ‘health economics’ and ‘decision making’ were debated in group-work sessions (GWS) to formulate recommendations and/or—if applicable—to state ‘pros’ and ‘contras’. Results A total of 13 different aspects were identified for modelling and HEE: model selection, time horizon of models, natural disease history, measures of vaccine-induced protection, duration of vaccine-induced protection, indirect effects apart from herd protection, target population, model calibration and validation, handling uncertainty, discounting, health-related quality of life, cost components, and perspectives. For decision making, there were four aspects regarding the purpose and the integration of HEEs of vaccines in decision making as well as the variation of parameters within uncertainty analyses and the reporting of results from HEEs. For each aspect, background information and an expert consensus were formulated. Conclusions There was consensus that when HEEs are used to prioritize healthcare funding, this should be done in a consistent way across all interventions, including vaccines. However, proper evaluation of vaccines implies using tools that are not commonly used for therapeutic drugs. Due to the complexity of and uncertainties around vaccination, transparency in the documentation of HEEs and during subsequent decision making is essential.